Costa Rica extradites two alleged drug traffickers to the US
By Alvaro Murillo
SAN JOSE, Aug 13 (Reuters) - Costa Rica has extradited two alleged drug traffickers to the U.S. to face charges, Costa Rica's attorney general said on Thursday, identifying the suspects as Gilbert Bell Fernandez, known as Macho Coca, and Gabriel Lozano, nicknamed Compadre.
They are due to face trial in U.S. federal court in New York.
The U.S. imposed sanctions on Bell, 62, in 2023 for what it said was his "significant role in the recent transformation of Costa Rica into a major narcotics transit hub." He had been jailed in San Jose since 2024 on charges of stealing state-owned fuel.
Authorities accuse Lozano, a Colombian who obtained Costa Rican citizenship, of using the country as a key transit point for cocaine moving from South American producers to markets farther north.
Costa Rica Attorney General Carlo Diaz said in a video statement that the extraditions were the result of cooperation with U.S. and international authorities "in which we share common objectives in the fight against crime, especially international drug trafficking."
Confronted with a surge in violence tied to the spread of drug trafficking groups, Costa Rica in 2025 approved the extradition of its citizens on drug trafficking or terrorism charges.
The first Costa Ricans were extradited under the measure in March. Authorities have said about 20 Costa Rican suspects are currently facing extradition proceedings, along with a similar number of foreign nationals.
(Reporting by Alvaro Murillo; Writing by Fabiola Arámburo; Editing by Cynthia Osterman)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple facing $2.7 billion UK lawsuit over 'unfair' app tracking rules
- Basketball-US prepare for toughest-ever World Cup with Wilson's sudden absence
- Malta government seeks to calm tensions after acquittal in journalist murder trial
Create E-mail Alert Related Categories
ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share